ArticleJPRAS open2026
Full-face aesthetic treatment with onabotulinumtoxin A: Results from a retrospective real world analysis.
Article in JPRAS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Full-face aesthetic treatment with neuromodulators is common in routine practice but not widely analyzed in clinical studies. Methods: This was a retrospective, two-center chart review evaluating the effectiveness and safety of full-face onabotulinumtoxinA injections for the aesthetic treatment of adult females, all of whom had severe forehead lines at baseline. Patients received a total dose of 114 U: 64 U in the upper face using the on-label treatment pattern for glabellar, crow's feet, and forehead lines; 20 U per side in the jawline based on the recently proposed "toxin lift" method; and 10 U in the chin. Results: Thirty-three females were included (mean age: 42.5 ± 7.6 years). Physician-rated forehead line severity improved from "severe" to "mild" or "none" in all patients at 4 weeks, as assessed using the Facial Wrinkle Scale and Forehead Lines Grading Scale. All study participants showed greater facial symmetry, enhanced jawline contour, and high patient satisfaction (FACE-Q Satisfaction with Outcome, 83.9 ± 9.0; Satisfaction with Forehead and Eyebrows, 95.4 ± 5.7). Adverse events were minor and transient. Conclusions: Full-face onabotulinumtoxinA was effective in reducing facial lines and improving overall symmetry and jawline contour, with high levels of patient satisfaction, and a favorable safety profile. Level of Evidence: Level III.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.